S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Stock market today: Another winning week for Wall Street ends with more records
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
One year after buying a failed bank, New York Community Bancorp is struggling
Critical asset just had biggest fall on record (Ad)
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
How major US stock indexes fared Friday, 3/1/2024
Critical asset just had biggest fall on record (Ad)
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Stock market today: Another winning week for Wall Street ends with more records
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
One year after buying a failed bank, New York Community Bancorp is struggling
Critical asset just had biggest fall on record (Ad)
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
How major US stock indexes fared Friday, 3/1/2024
Critical asset just had biggest fall on record (Ad)
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Stock market today: Another winning week for Wall Street ends with more records
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
One year after buying a failed bank, New York Community Bancorp is struggling
Critical asset just had biggest fall on record (Ad)
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
How major US stock indexes fared Friday, 3/1/2024
Critical asset just had biggest fall on record (Ad)
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Stock market today: Another winning week for Wall Street ends with more records
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
One year after buying a failed bank, New York Community Bancorp is struggling
Critical asset just had biggest fall on record (Ad)
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
How major US stock indexes fared Friday, 3/1/2024
Critical asset just had biggest fall on record (Ad)
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
NASDAQ:VYNE

VYNE Therapeutics (VYNE) Stock Price, News & Analysis

$2.22
-0.01 (-0.45%)
(As of 03/1/2024 ET)
Today's Range
$2.11
$2.25
50-Day Range
$1.71
$2.60
52-Week Range
$1.67
$8.73
Volume
90,975 shs
Average Volume
118,478 shs
Market Capitalization
$30.99 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.38

VYNE Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
232.2% Upside
$7.38 Price Target
Short Interest
Healthy
0.30% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.81mentions of VYNE Therapeutics in the last 14 days
Based on 9 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($4.82) to ($2.10) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.20 out of 5 stars

Medical Sector

383rd out of 951 stocks

Pharmaceutical Preparations Industry

180th out of 431 stocks


VYNE stock logo

About VYNE Therapeutics Stock (NASDAQ:VYNE)

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan-BET inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule bromodomain and extra-terminal inhibitor for the treatment of immuno-inflammatory indications; and FMX114, a combination gel formation of tofacitinib and fingolimod, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

VYNE Stock Price History

VYNE Stock News Headlines

This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Recap: VYNE Therapeutics Q3 Earnings
See More Headlines
Receive VYNE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for VYNE Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
3/01/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:VYNE
Fax
N/A
Employees
12
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$7.38
High Stock Price Target
$9.00
Low Stock Price Target
$5.75
Potential Upside/Downside
+232.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-23,210,000.00
Net Margins
-9,098.59%
Pretax Margin
-8,324.58%

Debt

Sales & Book Value

Annual Sales
$480,000.00
Book Value
$9.67 per share

Miscellaneous

Free Float
13,706,000
Market Cap
$30.99 million
Optionable
Not Optionable
Beta
1.18
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report














VYNE Stock Analysis - Frequently Asked Questions

Should I buy or sell VYNE Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for VYNE Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VYNE shares.
View VYNE analyst ratings
or view top-rated stocks.

What is VYNE Therapeutics' stock price target for 2024?

1 brokers have issued twelve-month price targets for VYNE Therapeutics' stock. Their VYNE share price targets range from $5.75 to $9.00. On average, they expect the company's share price to reach $7.38 in the next year. This suggests a possible upside of 232.2% from the stock's current price.
View analysts price targets for VYNE
or view top-rated stocks among Wall Street analysts.

How have VYNE shares performed in 2024?

VYNE Therapeutics' stock was trading at $2.33 at the start of the year. Since then, VYNE shares have decreased by 4.7% and is now trading at $2.22.
View the best growth stocks for 2024 here
.

Are investors shorting VYNE Therapeutics?

VYNE Therapeutics saw a decline in short interest in the month of February. As of February 15th, there was short interest totaling 35,800 shares, a decline of 31.8% from the January 31st total of 52,500 shares. Based on an average daily trading volume, of 101,100 shares, the days-to-cover ratio is currently 0.4 days. Approximately 0.3% of the company's shares are short sold.
View VYNE Therapeutics' Short Interest
.

When is VYNE Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our VYNE earnings forecast
.

How were VYNE Therapeutics' earnings last quarter?

VYNE Therapeutics Inc. (NASDAQ:VYNE) released its earnings results on Wednesday, November, 10th. The company reported ($6.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($5.94) by $0.54. The company had revenue of $4.09 million for the quarter, compared to analyst estimates of $4.67 million. VYNE Therapeutics had a negative trailing twelve-month return on equity of 136.48% and a negative net margin of 9,098.59%. During the same period last year, the company posted ($10.80) earnings per share.

When did VYNE Therapeutics' stock split?

VYNE Therapeutics's stock reverse split on the morning of Monday, February 13th 2023. The 1-18 reverse split was announced on Monday, February 13th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, February 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

What other stocks do shareholders of VYNE Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other VYNE Therapeutics investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Novan (NOVN), Organigram (OGI), Zosano Pharma (ZSAN), KushCo (KSHB), Bionano Genomics (BNGO), Pennsylvania Real Estate Investment Trust (PEI), Sorrento Therapeutics (SRNE) and Aeterna Zentaris (AEZS).

Who are VYNE Therapeutics' major shareholders?

VYNE Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Eventide Asset Management LLC (9.99%), Citadel Advisors LLC (8.46%), Parkman Healthcare Partners LLC (4.99%), Palo Alto Investors LP (3.19%), Prelude Capital Management LLC (0.85%) and Exome Asset Management LLC (0.85%). Insiders that own company stock include Mutya Harsch, Patrick G Lepore and Perceptive Advisors Llc.
View institutional ownership trends
.

How do I buy shares of VYNE Therapeutics?

Shares of VYNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VYNE) was last updated on 3/2/2024 by MarketBeat.com Staff